68Ga-DOTA-Olmutinib

N/A

Report date: 2025/10/22 16:10:26

Base Information

Drug Name68Ga-DOTA-Olmutinib
Drug Alias NameN/A
ClassificationRadiation-emitting products > Nuclides > Gallium > 68GaRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Radionuclide Drug Conjugates
Mechanisms of ActionEGFR T790M inhibitors
TargetsEGFR T790M
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesMassachusetts General HospitalFudan University Shanghai Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesFudan University Shanghai Cancer CenterMassachusetts General Hospital
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A